Wall Street brokerages expect Hill-Rom Holdings, Inc. (NYSE:HRC) to report sales of $675.10 million for the current quarter, Zacks reports. Four analysts have provided estimates for Hill-Rom’s earnings, with estimates ranging from $669.40 million to $679.80 million. Hill-Rom posted sales of $669.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.8%. The firm is scheduled to issue its next quarterly earnings results on Friday, January 25th.

On average, analysts expect that Hill-Rom will report full-year sales of $2.89 billion for the current year. For the next financial year, analysts expect that the company will post sales of $2.99 billion, with estimates ranging from $2.97 billion to $3.01 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Hill-Rom.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings data on Friday, November 2nd. The medical technology company reported $1.63 EPS for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.12. The firm had revenue of $759.20 million for the quarter, compared to analysts’ expectations of $750.90 million. Hill-Rom had a net margin of 8.86% and a return on equity of 21.10%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.32 EPS.

HRC has been the topic of a number of research reports. Barclays initiated coverage on shares of Hill-Rom in a research note on Monday, October 15th. They issued an “equal weight” rating and a $95.00 price objective on the stock. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th. Zacks Investment Research cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Wednesday, November 14th. UBS Group initiated coverage on shares of Hill-Rom in a research note on Tuesday, November 27th. They issued a “buy” rating and a $115.00 price objective on the stock. Finally, Raymond James increased their price objective on shares of Hill-Rom from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, November 5th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $104.00.

NYSE HRC traded down $2.99 during trading hours on Wednesday, reaching $92.76. The company’s stock had a trading volume of 494,073 shares, compared to its average volume of 400,213. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 1.33 and a beta of 0.94. Hill-Rom has a fifty-two week low of $78.16 and a fifty-two week high of $99.81. The company has a current ratio of 1.74, a quick ratio of 1.30 and a debt-to-equity ratio of 1.11.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Friday, December 14th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.86%. Hill-Rom’s dividend payout ratio (DPR) is 16.84%.

In other Hill-Rom news, SVP Andreas G. Frank sold 7,454 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $95.76, for a total value of $713,795.04. Following the transaction, the senior vice president now directly owns 27,224 shares in the company, valued at approximately $2,606,970.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.90% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC purchased a new position in Hill-Rom in the 2nd quarter valued at about $173,000. Quantbot Technologies LP lifted its holdings in shares of Hill-Rom by 270.2% during the 3rd quarter. Quantbot Technologies LP now owns 2,051 shares of the medical technology company’s stock worth $193,000 after acquiring an additional 1,497 shares during the period. First Light Asset Management LLC purchased a new position in shares of Hill-Rom during the 3rd quarter worth about $202,000. CAPROCK Group Inc. purchased a new position in shares of Hill-Rom during the 3rd quarter worth about $211,000. Finally, Johanson Financial Advisors Inc. purchased a new position in shares of Hill-Rom during the 3rd quarter worth about $221,000. Institutional investors own 82.59% of the company’s stock.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.